Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Molecure (WSE: MOC)

Last close As at 21/11/2024

20.00

▲ 0.08 (0.40%)

Market capitalisation

281m

Latest Insights

View More

Healthcare | Flash note

Molecure — Progressing the validation of mRNA platform

Healthcare | Update

Molecure — Q323 report highlights clinical progress

Healthcare | Update

Molecure — Striving to maximise clinical potential

Healthcare | Update

Molecure — Ramp-up in preparation for busy clinical year
molecure01
Visit Website

Sector

Healthcare

Balance Sheet

Forecast net debt (PLNm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 2.0 10.6 36.1
Relative 1.6 (10.2) 8.2
52 week high/low 25.6gr/14.5gr

Financials

Edison Investment Research is terminating coverage on Molecure (MOC). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Dec Revenue (PLNm) EBITDA (PLNm) PBT (PLNm) EPS (fd) (gr) P/E (x) P/CF (x)
2021A 1.5 (14.9) (13.6) (98.0) N/A N/A
2022A 1.6 (17.3) (15.3) (109.0) N/A N/A
2023E N/A N/A N/A N/A N/A N/A
2024E N/A N/A N/A N/A N/A N/A

Research

molecure01

Update

Healthcare

Molecure — An important year for R&D approaches

Initiation

Healthcare

Molecure — Novel approaches for problematic diseases

Healthcare

Flash note

Molecure — Clinical trials initiated for second asset

Flash note

Healthcare

Molecure — Clinical trials initiated for second asset
molecure01

Update

Healthcare

Molecure — An important year for R&D approaches

Initiation

Healthcare

Molecure — Novel approaches for problematic diseases

thematic

Healthcare

ASCO 2023 key takeaways

thematic

Healthcare

Machine learning in drug development

thematic

Healthcare

Outlook for 2023: Biotechs remain central to novel drug development
Cancer cells

thematic

Healthcare

Oncology ABCs (part four): Blood cancers (AML) – notable innovations
cell DNA double helix

thematic

Healthcare

Cell and gene therapies

thematic

Healthcare

Drug delivery platforms

thematic

Healthcare

Oncology ABCs (part three) – thinking outside the box in women’s cancer

thematic

Healthcare

Neuroscience comeback

thematic

Consumer

IPO apocalypse

thematic

Healthcare

Oncology ABCs (part two) – vaccines: niche no longer

thematic

TMT

ESG, moving beyond the box tick

thematic

Healthcare

Oncology ABCs (part one) – a small-cap biopharma prospectus series

thematic

Healthcare

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

thematic

Healthcare

Artificial intelligence in drug discovery

thematic

Healthcare

Biosynthesis – Taking the cannabinoid market to new heights

thematic

Healthcare

Seven things every investor should know about SIGA technologies & biological weapons

thematic

Healthcare

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

thematic

Healthcare

Edison Exhibits- antibiotic development

thematic

Healthcare

The next wave in AMD

thematic

Healthcare

The A-B-T of biosimilars- Explaining contemporary life science issues

thematic

Healthcare

Cannabinoid Therapies- The coming retail wave

thematic

Healthcare

Cannabinoid Therapies- Therapeutics turning a corner

thematic

Healthcare

Trial outcomes and value – Explaining contemporary clinical trial issues

thematic

Healthcare

Drug pricing – Market access and reimbursement

thematic

Healthcare

The diagnostics sector

thematic

Healthcare

ASCO 2017

thematic

Consumer

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Healthcare

Edison healthcare quarterly: A boost for allergy immunotherapy

thematic

Energy & Resources

ASX Spotlight Conference – London, 6 March 2014

thematic

Energy & Resources

ASX Small to Mid Caps Conference – London, 7 March 2013

thematic

Healthcare

Edison healthcare quarterly: Boom times for US biotech

thematic

Healthcare

Edison healthcare quarterly: Crisis? What crisis?

thematic

Healthcare

Edison healthcare quarterly: How to please some of the people some of the time